Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
about
Strategies for early detection of resectable pancreatic cancerImproving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysisThe clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updatesEndoscopic ultrasound-guided techniques for diagnosing pancreatic mass lesions: Can we do better?Biomarker discovery from pancreatic cancer secretome using a differential proteomic approachIdentification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis.Serum CA19-9 in patients with solid pancreatic mass.Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer.Developments in serologic detection of human pancreatic adenocarcinoma.Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression.Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility.Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method.Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft.Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunctionIdentification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases.Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer.Increased serum CA 19-9 antibodies in Sjögren's syndrome.CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trialsNeutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreasDecrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancerPrognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabinePatients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients.Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis.Preoperative evaluation and management of the pancreatic head mass.Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas.Current and future therapies for advanced pancreatic cancer.Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer.Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer?Liver Abscess With a Markedly High Level of Carbohydrate Antigen 19-9.Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk.Cystic pancreatic tumors (CPT): predictors of malignant behavior.Smoking and serum CA19-9 levels according to Lewis and secretor genotypes.Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
P2860
Q24564006-61B5297D-9E5E-484C-AE96-A0F6A72E02EBQ26782719-E0B020CF-4A81-4973-ACA5-08157452E4B5Q26865015-78DA9F63-425E-418C-AFAF-A9F3D40BBDD3Q28073687-2459B523-BE1B-473A-93EC-5304E2E3B865Q28276398-5F74A102-FA96-4857-B6D2-A7A9DCB4E1F6Q33506167-1EAC85F5-9CFD-4D57-83E6-4E3F9756A5ACQ33596555-FF8EC898-AC5E-4104-9F5C-320DAF096D76Q33699291-55A5A6E7-C887-48EA-A27F-55444C92B76BQ33752171-FA8D8AE3-285A-4531-8B92-1CA13705A144Q33803923-38ABFFB1-5AC2-495C-9C67-11591D73E746Q33828558-212FBDB1-1521-45BE-AF0E-F2F7706EBC1FQ34558669-8D0962CD-548D-488E-80EA-8859F411E8A1Q34669441-86D32EDF-1972-4754-855F-480C841136A6Q34958895-DC532D63-0D5B-470D-BED4-13CAE2B3A121Q35046670-9701440F-894D-46EF-BDE3-8794E5F03573Q35059946-63D25A13-F5CC-4F81-AEBA-9CFEF5AE7B6EQ35983251-AE6A7C5F-9748-46E4-B6F2-14B48FC3FF98Q36452789-CB7543C7-9077-402D-8D48-6ADCEC93F4E5Q36570435-7C1834C7-3D3D-448A-B781-FAB61D642474Q36613376-0AA36A3E-BABD-4599-A517-0DF208925FD7Q36615381-F82D857C-37AC-4401-A5FB-49ABCF4356F4Q36625481-56122D9A-602D-4B13-8B7E-9B79ACC89B47Q36641445-454D3909-D41C-45DA-8D4E-4A7539C4D4A8Q36671332-89BC3B6C-9E69-46D0-9332-3D21E176B42DQ37701172-DBBC6035-3607-416C-8D01-BC229D4B6709Q37714287-87D9FD21-0A18-4585-A41E-CB48F8453F06Q38016795-E9C13A68-F616-41DC-8FDD-DFE1C042ED57Q38018315-51216A18-BA9A-4377-9F13-8FE5B82FDA6BQ38021384-126338FF-6BEA-4427-B05D-291FF7BF03B3Q38115619-2EF91798-1083-4B02-AA5C-735A05A7A905Q38673621-E1C1B075-111D-4FC4-8699-6D091C21F109Q40837209-25F29C76-8737-4018-9CE8-4563B0DDE405Q41191788-1061D9CB-94EE-4ED1-9B22-A0CBD1BC52FEQ41330194-7FAF0CAA-4EDD-472D-AD77-FF972DD8ED0CQ42120739-17BDBFE5-F6FB-426E-AE62-974D9453977FQ42238114-8B947F1E-D3DA-483E-B0FC-E5CF6480A614Q44178438-2BBAE9A2-323A-4F76-840E-A274BA61F26FQ44353145-D943EDCB-24E4-422D-87B5-4C4DA246CF97Q46358023-68CA8020-BC43-431D-B233-606C7A07839CQ46723443-75DED941-80EF-4BA3-947F-DF29467B6EDD
P2860
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
@en
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
@nl
type
label
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
@en
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
@nl
prefLabel
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
@en
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
@nl
P2093
P1476
Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer.
@en
P2093
P304
P356
10.7326/0003-4819-110-9-704
P407
P577
1989-05-01T00:00:00Z